Abstracts
8 June 2009
Vol. 2 No. 7 (2006)
https://doi.org/10.4081/hmr.v2i7.402

Combined modality treatment for early-stage Hodgkin’s lymphoma: the GHSG experience

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
202
Views
1085
Downloads

Authors

S Sasse
support@pagepress.org
V Diehl
A Engert
The prognosis of patients has substantially improved over the last decades. Currently, approximately 80% of all patients remain disease free 5 years after treatment.1 On the basis of clinical staging and risk factors as listed in Table 1 patients with Hodgkin lymphoma (HL) are usually classified into early favourable stages (CS 1-2 without risk factors), early-unfavorable stages (CS I-II with risk factors) or advanced stages. Here, we report on the experience of the GHSG and others in the treatment of early favourable and unfavourable HL.

Altmetrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite



Combined modality treatment for early-stage Hodgkin’s lymphoma: the GHSG experience. (2009). Hematology Meeting Reports, 2(7). https://doi.org/10.4081/hmr.v2i7.402